|
Motley fool //
(Preview)
Recs Back to Yahoo!Are Insurers Playing Fair With HIV Patients?By Todd Campbell | More Articles | Save For Later July 20, 2014 | A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insur...
|
Huey
|
0
|
717
|
|
|
|
|
FibroScans now Available in US
(Preview)
Not a question, but just an update on the FibroScan technology in the US which is a non-invasive method to measure fibrosis staging (replacing the needle biopsy). In 2013 the FDA approved the FibroScan technology and in 2014 the AASLD endorsed the FibroScan technology. The FibroScan is technicall...
|
Luckydog1953
|
7
|
2057
|
|
|
|
|
New HIV Drugs are now covered by obomacare
(Preview)
http://www.fool.com/investing/general/2014/07/13/obamacares-surprising-hiv-drug-demand.aspx
|
Huey
|
0
|
720
|
|
|
|
|
Japan Approves First All-Oral, Ribavirin-Free Hep C Treatment, Daklinza (daclatasvir) and Sunvepra (asunaprevir)
(Preview)
Monday, July 7, 2014. PRINCETON, N.J. Bristol-Myers Squibb Company announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra(asunaprevir), a NS3/...
|
Cinnamon Girl
|
2
|
1404
|
|
|
|
|
BMS Receives Positive CHMP Opinion for daclatasvir (`Daklinza`) in the EU
(Preview)
PRINCETON, N.J.-- 27 June, 2014. Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS...
|
Cinnamon Girl
|
1
|
1207
|
|
|
|
|
Australia New Zealand - TGA approves Gilead's Sovaldi
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2014/07/hepatitis-c-news-australia-new-zealand.html
|
OldenSlow
|
6
|
1671
|
|
|
|
|
Researchers extend liver preservation for transplantation
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2014/06/nih-funded-researchers-extend-liver.html
|
OldenSlow
|
1
|
842
|
|
|
|
|
T-cells
(Preview)
http://news.yahoo.com/designer-t-cells-fight-viruses-transplants-191027539.html
|
Huey
|
2
|
1032
|
|
|
|
|
US Gov't to Investigate High Price of Sovaldi
(Preview)
The people who run the IRS, Post Office, VA, ACA, Medicare are now involved - I feel so much better that this is going to be resolved SOON! longld The $84,000 Price Tag On Gilead's Hepatitis C Treatment Sovaldi Has Evoked Sharp Criticism From Several Quarters. The drug was released in January and sin...
|
longld
|
1
|
869
|
|
|
|
|
AbbVie All-Oral Hep C Therapy gets Rapid EU Review
(Preview)
(Reuters) - European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment. The U.S. drugmaker said on Tuesday the move by the European Med...
|
Cinnamon Girl
|
0
|
989
|
|
|
|
|
U.S. FDA Grants Priority Review to AbbVie for Investigational All-Oral Therapy for the treatment of Gen 1
(Preview)
June 13, 2014 AbbVie announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (F...
|
Cinnamon Girl
|
0
|
641
|
|
|
|
|
Sovaldi is going to be paired up with other DAA's to shorten the time on treatment.
(Preview)
n the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks. Bristol-Myers disclosed plans for the exploratory 30-patient t...
|
Huey
|
1
|
954
|
|
|
|
|
New Four Week Treatment to Start Testing
(Preview)
It just keeps getting BETTER and BETTER !!! Exclusive: A four-week hep C cure? Bristol to test drugs with Gilead's Sovaldi SuziQ
|
suziq
|
0
|
718
|
|
|
|
|
USA Ranks last in Health Care.
(Preview)
.Source: The Commonwealth Fund Lead author Karen Davis, of Johns Hopkins Bloomberg School of Public Health, says the findings were disappointing, but not surprising. This is the fifth time in a row that the U.S. has landed at the bottom of the heap in the semi-annual report, in large part due to the f...
|
Huey
|
3
|
1322
|
|
|
|
|
NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
(Preview)
In draft recommendations published on 16th June 2014 healthcare guidance body NICE (the National Institute for Health and Care Excellence) is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C.Commenting on the draft guid...
|
Cinnamon Girl
|
2
|
1418
|
|
|
|
|
June 2014 HCV Advocate Newsletter
(Preview)
website...http://www.hcvadvocate.org/news/newsLetter/2014/advocate0614.html
|
Cinnamon Girl
|
2
|
849
|
|
|
|
|
Scottish Medical Consortium advise restricted access to sofosbuvir on NHS in Scotland
(Preview)
The Scottish Medicines Consortium (SMC) has today published its advice on the use of the drug sofosbuvir on the NHS in Scotland. The body of experts have "accepted sofosbuvir for restricted use in patients with genotypes 1 to 6."The SMC go on to make the following specific restrictions:Use in treat...
|
Cinnamon Girl
|
7
|
1331
|
|
|
|
|
Merck is buying Idenix - More new drugs???
(Preview)
http://www.marketsemerging.com/2-stocks-everyone-is-talking-about-idenix-pharmaceuticals-inc-nasdaqidix-international-game-technology-nyseigt/179394/
|
Jener
|
0
|
711
|
|
|
|
|
Quebec Approves Sovaldi Reimbursement
(Preview)
Priority Review by INESSS Provides Recommendation to Treat Patients with Genotypes 1 and 4 HCV Infection Regardless of Fibrosis Level Montreal, June 2, 2014 /CNW/ - "Gilead Sciences Canada, Inc. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi® (s...
|
OldenSlow
|
3
|
1652
|
|
|
|
|
Clinical trials started for TT-034 an injectable hcv tx.
(Preview)
Pretty interesting article about new clinical trial involving one injection of TT-034. SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) announced that it has dosed the first patient in its 'first in man', Phase I/IIa clinical tria...
|
maddie
|
0
|
792
|
|
|
|
|
Link to a news flash
(Preview)
http://www.hepmag.com/articles/south_carolina_hepatitis_b_lawsuits_2831_25641.shtml
|
Huey
|
0
|
965
|
|
|
|
|
Sofosbuvir Based Hepatitis C Clinical Trials - Recruiting
(Preview)
recruiting...http://hepatitiscnewdrugs.blogspot.co.uk/2014/05/updates-sofosbuvir-based-hepatitis-c.html
|
Cinnamon Girl
|
0
|
954
|
|
|
|
|
Medicare Eases Restrictions On Pricey Hepatitis C Treatment
(Preview)
"The shift has come about because of an Arizona man named Walter Bianco who was twice denied Medicare coverage for two new drugs that together cost about $150,000. But those denials were reversed this week after Shots and NPR's Morning Edition reported on Bianco's case. Bianco has been infe...
|
OldenSlow
|
5
|
2112
|
|
|
|
|
Simeprevir approved in the European Union for the treatment of adults with hep C genotype 1 and 4
(Preview)
Press Release, Stockholm, Sweden - Medivir AB announces that simeprevir has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C in combination with other medicinal products.OLYSIO (Simeprevir) provides a...
|
Cinnamon Girl
|
0
|
794
|
|
|
|
|
HCV News and Updates
(Preview)
I get email updates containing random new, sometimes dated, yet occasionally interesting articles. Take a look and see what you think, who knows, you might find the answer to that question that kept you awake all night, or maybe not, but it's all food for thought! TigPCP training program increased...
|
Tig
|
5
|
1140
|
|
|
|
|
Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation
(Preview)
"An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49th annual meeting of the European Associ...
|
Cinnamon Girl
|
0
|
955
|
|
|
|
|
May 2014 HCV Advocate Newsletter
(Preview)
This month`s newletter from the HCV Advocate website includes reports from the NEJM (New England Journal of Medicine) and EASL 2014 (European Association for the Study of the Liver) on the latest drug developments, as well as other articles of interest.[url]http://www.hcvadvocate.org/news/...
|
Cinnamon Girl
|
0
|
713
|
|
|
|
|
VA Approves Sovaldi
(Preview)
"The formulary decision by the VA comes as a panel assembled by the system last month recommended that doctors warehouse hepatitis C patients, putting those with advanced liver disease on Sovaldi first." "By triaging patients, health care providers can absorb the patient load -...
|
OldenSlow
|
3
|
863
|
|
|
|
|
Impact of SVR on Liver Fibrosis and Cirrhosis
(Preview)
Hello All Thought this article on SVR impact on cirrhosis was encouraging. This is a excerpt from the article The percentage with regression of cirrhosis Of these 137 patients who achieved an SVR, 73 (53%) patients had regression of cirrhosis. Conclusions; Our results suggest that the majorit...
|
Matt Chris
|
9
|
2221
|
|
|
|
|
Understanding the importance Resistant Variant (Q80K)
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2013/12/olys...
|
Matt Chris
|
12
|
2550
|
|
|
